A
André B.P. van Kuilenburg
Researcher at University of Amsterdam
Publications - 155
Citations - 8070
André B.P. van Kuilenburg is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Dihydropyrimidine dehydrogenase & DPYD. The author has an hindex of 36, co-authored 143 publications receiving 7001 citations.
Papers
More filters
Journal ArticleDOI
Histone deacetylases (HDACs): characterization of the classical HDAC family
Annemieke J.M. de Ruijter,Albert H. van Gennip,Huib N. Caron,Stephan Kemp,André B.P. van Kuilenburg +4 more
TL;DR: In this paper, a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity is presented.
Journal ArticleDOI
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
TL;DR: A deficiency of DPD appears to be an important pharmacogenetic syndrome, and patients with a partial DPD deficiency have an increased risk of developing grade IV neutropenia.
Journal ArticleDOI
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks,Linda M. Henricks,Gabe S. Sonke,Maarten J. Deenen,Tanja K. Froehlich,Ursula Amstutz,Carlo R. Largiadèr,Barbara A. Jennings,Anthony M. Marinaki,Jeremy D. Sanderson,Zdenek Kleibl,Petra Kleiblova,Matthias Schwab,Ulrich M. Zanger,Ulrich M. Zanger,Claire Palles,Ian Tomlinson,Eva Gross,André B.P. van Kuilenburg,Cornelis J. A. Punt,Miriam Koopman,Jos H. Beijnen,Jos H. Beijnen,Annemieke Cats,Jan H.M. Schellens,Jan H.M. Schellens +25 more
TL;DR: This systematic review and meta-analysis found that DPYD variants c.1679T>G and c.1236G>A/HapB3 are clinically relevant predictors of fluoropyrimidine-associated toxicity, and upfront screening for these variants, in addition to the established variants DPYD*2A andc.2846A>T, is recommended to improve the safety of patients with cancer treated with fluoropyridines.
Journal ArticleDOI
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Linda M. Henricks,Carin A.T.C. Lunenburg,Femke M. de Man,Didier Meulendijks,Geert W.J. Frederix,Emma Kienhuis,Geert Jan Creemers,Arnold Baars,Vincent O. Dezentjé,Alexander L T Imholz,Frank J.F. Jeurissen,Johanna E.A. Portielje,Rob L. H. Jansen,Paul Hamberg,Albert J. ten Tije,Helga J. Droogendijk,Miriam Koopman,Peter Nieboer,Marlène H.W. van de Poel,Caroline M.P.W. Mandigers,Hilde Rosing,Jos H. Beijnen,Jos H. Beijnen,Erik van Werkhoven,André B.P. van Kuilenburg,Ron H.N. van Schaik,Ron H.J. Mathijssen,Jesse J. Swen,Hans Gelderblom,Annemieke Cats,Henk-Jan Guchelaar,Jan H.M. Schellens,Jan H.M. Schellens +32 more
TL;DR: Overall, fluoropyrimidine-related severe toxicity was higher in DPYD variant carriers than in wild-type patients in this prospective, multicentre, safety analysis in 17 hospitals in the Netherlands, and relative risks for severe toxicity were compared between the current study and a historical cohort ofDPYD variant allele carriers treated with full dose fluoropyridine-based therapy.
Journal ArticleDOI
Increased risk of grade IV neutropenia after administration of 5‐fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation
TL;DR: Screening of patients at risk before administration of 5‐FU‐related toxicities in patients with low DPD activity and the apparently high prevalence of the IVS14+1G>A mutation is warranted.